Central Nervous System
Insights on the major trends in aging disorders and pain conditions including the development of targeted therapies in clinical trial designs and patient care.
Expert opinions on innovative processes include protocol design, site training, and real time data quality analysis in central nervous systems.
Traumatic brain injury trials
The manifestations and effects of TBI are varied and impact diverse populations. To improve prevention and therapy, we need to conduct further clinical research to evaluate and validate better strategies for diagnosis and disease characterisation. A better understanding of how TBI — mild and severe — manifests, can lead to better identification of biomarkers, and the development of prevention and treatment strategies.
Read the whitepaperKey considerations for Parkinson’s disease trials
While there are many advances in Parkinson’s Disease (PD), such as identification of new biomarkers to measure disease progression, valuable insights in study design coming from Alzheimer’s Disease trials, and creative approaches for patient recruitment, challenges still remain in this therapeutic area.
Read the whitepaperKey considerations in chronic pain clinical trials
There has been an increased prevalence of lifetime substance abuse, creating an urgent need for innovative pain medications without the use of opioids. Unfortunately, clinical development of non-opioid pain medications has been hindered by a massive placebo-response.In our whitepaper, we discuss the aspects of pain studies that sponsors will need to consider to ensure success of their chronic pain trial model.
Read the whitepaperBlogs, media article and webinar insights in central nervous system and Alzheimer's disease
Media article: The growing potential of neurological biomarkers as surrogate endpoints for accelerated drug development
This article by Dr. Peter Schueler explores how digital and liquid biomarkers are developing, and how they can impact the future of neurological studies.
Blog: The impact of the COVID-19 pandemic on mental health
Learn how the ongoing state of the COVID-19 pandemic has affected the global mental health crisis.
Media article: Biomarkers give clinical trials of neurodegenerative diseases a head start
Biomarkers that detect the molecular changes preceding the clinical symptoms of neurodegenerative disease, are critical for clinical trials at pre-symptomatic stages.
Blog: Leveraging in-home services for Parkinson’s Disease
New technologies like wearables and mobile devices, in-home services, and increased patient engagement can change the way we treat Parkinson's disease.
Blog: How to improve participation of asymptomatic patients in neurodegenerative disease registries
Insight into the power of patient-registries and how they can be used to increase participation of neurodegenerative patients.
Blog: Key considerations for disease-modifying Parkinson’s disease trials
Apart from the need to better manage symptoms in advanced stages of Parkinson's disease, there is an even greater need to develop neuro-protective or neuro-regenerative therapies.
Blog: The role of technology in Parkinson’s treatment and research
Constant study and innovation of Parkinson's Disease (PD) research has shown the implementation of medical devices, AI, and mobile applications pave the way forward.
Media article: Alzheimer’s - the search for a cure
A review of the current landscape of Alzheimer’s research and recently published study results.
Media article: Engaging the crowds
Patient registries need to be offering more support and convenience to ensure greater engagement and enrolment in clinical trials.
Media article: Parkinson’s disease clinical trials
A thought leadership article by Peter Schueler and Haichen Yang on the challenges, advancements and role of technology.
Media article: Key considerations for disease-modifying Parkinson’s disease trials
Lessons learnt from Alzheimer’s trials could help in Parkinson’s drug development.
Media article: Alzheimer’s in clinical trials
The atempt to develop a causal treatment against the progression of Alzheimer’s disease is an unparalleled series of nearly two decades of failures in drug development.
Media article: Applying disruptive innovation In CNS clinical trials to reduce variability
Research suggests that CNS drugs are 45% less likely to progress from Phase III to regulatory filing than other non CNS drugs.
Webinar: Improving patient adherence and outcome measurement with game design in healthcare
What are the proven benefits, which populations to target and what are the current challenges?
Receive more insights on the central nervous system
Please visit ICON's Preference Centre and select 'CNS, Pain and Ageing related disorders' under 'Therapeutic Areas of Interest' to receive new insights on rare and orphans diseasesCNs, Pain and Ageing related disorders..
Receive new insightsCNS, Pain and Ageing related disorders
ICON’s experience of CNS, Pain and Ageing related disorder studies comprises global and regional clinical research in all major areas of neurology, psychiatry and pain research, and all phases of clinical drug development. Read more about ICON's services.
Read more about ICON's services in CNS, Pain and Ageing related disorders